Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03675412 · ClinicalTrials.gov registry record · NA
Caffeine Consumption in Glaucoma Patients and Healthy Subjects
A NA study of Glaucoma, Primary Open Angle, sponsored by Wills Eye.
- Recruiting
- Registry status
- NA
- Development phase
- 80
- Enrollment target
- 1
- Study location
NCT03675412 is a NA study of Glaucoma, Primary Open Angle that is actively recruiting participants, run by Wills Eye. The registered enrollment target is 80 participants, above the 55-participant average among 5 other Glaucoma, Primary Open Angle trials with a reported enrollment target (45% higher). The trial reports 1 study location across 1 state.
The verdict
NCT03675412, a NA study of Glaucoma, Primary Open Angle, is actively recruiting participants, sponsored by Wills Eye.
- RECRUITING
- Registry status
- NA
- Development phase
- 80 participants
- Enrollment target
- 1
- Study location
Study Summary
Caffeine is the most widely consumed drinking nutrient in the world. Caffeine effects various organs and the vascular system. It decreases ocular blood flow due to vasoconstriction.
Conditions Studied
Interventions
- DIETARY_SUPPLEMENT Caffeine tablet
Study Locations (1)
Pennsylvania
- Wills Eye Glaucoma Service - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 80 participants |
| Start Date | 2018-12-30 |
| Est. Completion | 2026-12-31 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03675412
The ClinicalTrials.gov registry entry for NCT03675412 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 80 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 55-participant average among 5 other Glaucoma, Primary Open Angle trials with a reported enrollment target (45% higher). The listed sponsor is Wills Eye, which has 59 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Glaucoma, Primary Open Angle appearing as the primary indexed condition, and to 1 intervention - of which Caffeine tablet is the first listed.
NCT03675412 reports 1 study location spanning 1 distinct geographic area - top geographies include Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT03675412 about?
NCT03675412 is a clinical study titled "Caffeine Consumption in Glaucoma Patients and Healthy Subjects". Caffeine is the most widely consumed drinking nutrient in the world. Caffeine effects various organs and the vascular system. It decreases ocular blood flow due to vasoconstriction.
What is the current status of trial NCT03675412?
This trial is currently recruiting. It is a NA study. The enrollment target is 80 participants. The study started on 2018-12-30. Estimated completion is 2026-12-31.
What conditions does trial NCT03675412 study?
This clinical trial studies the following conditions: Glaucoma, Primary Open Angle.
What interventions are being tested in trial NCT03675412?
The interventions under investigation include: Caffeine tablet (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT03675412?
This trial is sponsored by Wills Eye, which has 59 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03675412 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Glaucoma, Primary Open Angle
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Adaptive Optics Retinal Imaging
RECRUITING · NA
-
Safety and Feasibility of the ELIOS System in POAG Patients
RECRUITING · NA
-
Safety and IOP-Lowering Effects of WB007
COMPLETED · Phase 1
-
Investigate, Following Cataract Surgery With IOL in Conjunction With Intracanalicular Dexamethasone Insert
COMPLETED · Phase 4
-
NT-501 CNTF Implant for Glaucoma: Safety, Neuroprotection and Neuroenhancement
COMPLETED · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.